Arpeggio Bio
Arpeggio Bio uses AI on large RNA-sequencing datasets to find drugs against transcription factors, the hard-to-hit proteins that switch cancer genes on, with a first programme in immunotherapy-resistant melanoma.
Overview
Arpeggio Bio combines high-throughput RNA sequencing with machine learning to discover small molecules that modulate transcription factors long considered undruggable, naming NRF2, TEAD and GPX4 among its targets. Its YC profile states that its lead programme was progressing towards a development candidate for melanoma resistant to checkpoint inhibitors and that the company had about $20 million in venture funding and partnerships with Johnson & Johnson and FORMA Therapeutics; those figures are the company's own and are not repeated as a funding row here. The company website returned an error when checked on 2026-09-10.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanyBlank Bio
Shares Y Combinator, RNA sequencing & expression profiling, AI-driven drug & target discovery and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanySerinus Biosciences
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyHarmonic Discovery
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyOncobox
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyAlgen Biotechnologies
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyData Driven Bioscience (Duoseq)
Shares Y Combinator, RNA sequencing & expression profiling and the tag yc.
- CompanyReverie Labs
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.